Day: July 1, 2024

Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, and its partner TAQA Arabia, signed a framework agreement during the Egypt-EU Investment Conference 2024, which was held on June 29 and 30 in Cairo. The Egypt-EU Investment Conference was held under the auspices of Ursula von der Leyen, President of the European Commission, and Abdel Fattah El-Sisi, President of the Arab Republic of Egypt. With its partner TAQA Arabia, Voltalia is continuing to develop a cluster combining renewable energy and green hydrogen production. The framework agreement is a continuation of a Memorandum of Understanding (MoU) signed in December 2022 to develop a cluster combining green hydrogen production with renewable power generation. The project will be implemented in two identical phases, each comprising a 500-megawatt...

KALMAR CORPORATION, STOCK EXCHANGE RELEASE, 1 July 2024 AT 9:15 AM (EEST) Composition of Kalmar Corporation’s Shareholders’ Nomination Board Kalmar Corporation’s (“Kalmar” or the “Company”) Shareholders’ Nomination Board (“Nomination Board”) has been appointed in accordance with the Charter of the Nomination Board approved by Cargotec Corporation’s (“Cargotec”) Annual General Meeting held on 30 May 2024, which also resolved on the partial demerger of Cargotec and the incorporation of Kalmar. The Nomination Board consists of four (4) members. According to the Charter of the Nomination Board, the members of the Nomination Board are appointed as follows: the two largest shareholders of class A shares are entitled to appoint one (1) member each, and the two largest shareholders of class B shares who do not own any class A shares, are entitled...

Saint Herblain (France), July 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The approval was unanimously endorsed by Member States following a stringent assessment by the European Medicines Agency (EMA)1. The EC decision marks the third approval the Company has received for IXCHIQ® following approval from the U.S. Food and Drug Administration (FDA) in November 2023 and Health Canada last month2. The Company expects to deliver the first doses in Europe in the fourth quarter of 2024. IXCHIQ® is the world’s only licensed chikungunya vaccine available to address...